Loading
Torqur is a Swiss company developing bimiralisib, a drug that blocks the PI3K and mTOR growth signals, as a tablet for cancer and as a skin gel for actinic keratosis, a sun-damage skin condition that can turn into skin cancer.
Torqur AG, based in Basel, was founded in 2021, according to the company, under the umbrella of Swiss Rockets AG, a Basel incubator, after acquiring the assets of Piqur Therapeutics AG, a University of Basel spin-off co-founded in 2011 by Vladimir Cmiljanovic to develop bimiralisib. Bimiralisib is a balanced pan-PI3K/mTOR inhibitor formulated for oral and topical use; the company states it has shown early clinical activity in several phase 1/2 studies. In August 2026 the European Commission granted oral bimiralisib orphan designation for thymic epithelial tumours, its first in a solid tumour, and the company also reports a collaboration with Lonza on the drug. Its only study registered on ClinicalTrials.gov, NCT06319794, a randomised phase 2 proof-of-concept study of topical bimiralisib gel in actinic keratosis, a precancerous skin lesion, was posted in March 2024 and is completed; it is not a cancer treatment trial.
Shares mTOR, PI3K, AKT and mTOR inhibitors.
Shares mTOR, PI3K, AKT and mTOR inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/